[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Englewood Hospital and Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":138},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,68,92,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100622847","pilot-study-of-mammogrip-for-breast-positioning-image-quality-and-patient-comfort-in-mammography-100622847",false,"NCT07388940","Pilot Study of MammoGRIP for Breast Positioning, Image Quality, and Patient Comfort in Mammography","MammoGRIP","Inclusion Criteria:\n\n* Women aged 40-75 years undergoing routine screening or diagnostic mammography\n* Ability to provide informed consent\n* Prior mammogram results are available for the patient in Epic\n\nExclusion Criteria:\n\n* History of bilateral mastectomy\n* Active skin condition or open wounds on the breast or chest\n* Known allergy to components of MammoGRIP®","FEMALE","40 Years","75 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","To evaluate the effectiveness of MammoGRIP® in improving mammographic image quality and minimizing repeated breast positioning compared to standard practice without MammoGRIP®.",[27],"Mammography",[29],"Mammogram","NOT_YET_RECRUITING","2026-01-28",{"date":33,"type":34},"2026-02-05","ACTUAL",{"date":36,"type":21},"2026-02",{"date":38,"type":21},"2027-02",{"name":40,"class":41},"Englewood Hospital and Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100590707","early-phase-1-pilot-study-evaluating-the-advantages-of-sucrosomial-iron-post-operative-supplementation-vs-standard-of-care-after-cardiac-surgery-100590707","NCT06970925","Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery","Pilot Study Evaluating Efficacy and Economic Advantage of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care in Patients After Cardiac Surgery","Inclusion Criteria:\n\n* ICU hospitalized patients who underwent non-emergent cardiac surgery\n* Post operative iron deficient or anemic patients (Hb\\\u003C 12 for both men and women).\n* Patients following the same pre-operative protocol\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Post operative day 1 Hg \\\u003C9\n* Age \\>90 years\n* Patients with cancer or other chronic conditions that impair erythropoiesis (e.g. MDS)\n* Stage 3, 4 renal disease\n* Intraoperative transfusion of PRBC","ALL","18 Years",{"count":53,"type":21},40,[55],"EARLY_PHASE1","Primary objective: to evaluate the non-inferiority in terms of improvement of hemoglobin (Hg) levels within 30 days postoperatively between two proposed treatments.\n\nSecondary objective: to evaluate the financial costs associated with Sucrosomial® Iron treatment compared to Iron Sucrose (IV), while demonstrating non-inferiority in the improvement of hemoglobin levels, reduction in transfusion requirements, and reduction of hospital\u002FICU stay length",[58],"Cardiac Surgery","RECRUITING","2025-08-04",{"date":62,"type":34},"2025-08-07",{"date":64,"type":34},"2025-06-30",{"date":66,"type":21},"2026-06-30",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":42},"100568483","novel-method-to-assess-hepatic-regeneration-and-predict-hepatic-related-morbidity-after-partial-hepatectomy-100568483","NCT06681818","Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy","Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy","Inclusion Criteria:\n\n* Patient plans to have partial liver resection for primary liver pathology or metastatic disease\n* Patient is able to comprehend and willing to sign the written consent form\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years\n* Patients identified as members of a vulnerable population, except women of child bearing potential with negative pregnancy test",{"count":76,"type":21},125,[24],"the investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection (2) to assess the production of CO in patients following liver resection and correlate these findings to the rate of liver regeneration and liver function.",[80,81],"Liver Cancer Adult","Liver Regeneration",[83],"hepatectomy","2025-07-18",{"date":86,"type":34},"2025-07-23",{"date":88,"type":21},"2025-11-21",{"date":90,"type":21},"2039-01-01",{"name":40,"class":41},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":42},"100588176","outcomes-of-ablation-of-unresectable-pancreatic-cancer-using-the-nanoknife-irreversible-electroporation-system--100588176","NCT06937996","Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-","Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System","Inclusion Criteria:\n\n* \\> = 18 years of age\n* Must be found to have locally advanced unresectable disease following standard chemotherapy ± radiotherapy as demonstrated with either CT\u002FMRI imaging and surgical evaluation, and not have taken any chemotherapy\u002Fradiotherapy within 5 weeks of treatment with the NanoKnife IRE System\n* Must have an INR \\\u003C 1.5\n* Are willing and able to comply with the protocol requirements\n* Are able to comprehend and willing to sign an informed consent form\n\nExclusion Criteria:\n\n* Creatinine \\> 2.0 mg\u002FdL\n* Any lab value with a grade 3 or 4 toxicity as defined by the CTCAE Version 5.0\n* Inability to stop antiplatelet and coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System\n* Tumor size not measurable\n* Known history of contrast allergy that cannot be medically managed\n* Known hypersensitivity to the metal in the electrodes (stainless steel 304L) that cannot be medically managed\n* Unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atracurium, cisatracurium, etc.)\n* Women who are pregnant or currently breast feeding\n* Women of childbearing potential who are not utilizing an acceptable method of contraception\n* Have taken an investigational agent within 30 days of visit 1\n* Have implanted cardiac pacemakers or defibrillators\n* Have implanted electronic devices or implants with metal parts in the vicinity of a lesion\n* Have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation)\n* Have a recent history of myocardial infarction (within the past 2 months)\n* Have Q-T intervals greater than 550 ms unless treated with an Accysync Model 72 synchronization system controlling the NanoKnife system's output pulses\n* Evidence of distant metastases of stage IV\n* Have taken any chemotherapeutic agent within 5 weeks of treatment with the NanoKnife Irreversible Electroporation (IRE) System\n* Received non-conventional fractionation schedules, such as stereotactic radiation (5 fractions or less) or received higher than 54 Gray (Gy) delivered conventionally",{"count":100,"type":21},25,"OBSERVATIONAL","The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.",[104],"Pancreatic Cancer Non-resectable","2025-06-12",{"date":107,"type":34},"2025-06-17",{"date":109,"type":34},"2025-05-13",{"date":111,"type":21},"2035-05-31",{"name":40,"class":41},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":42},"100201977","fecal-microbiota-transplantation-for-c-diff-infection-100201977","NCT01905709","Fecal Microbiota Transplantation for C Diff Infection","Fecal Microbiota Transplantation for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)","Inclusion Criteria:\n\n1. Subject is at least 18 years old.\n2. Subject has recurrent or relapsing CDI defined as:\n\n   * At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, fidaxomicin). OR\n   * At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity. OR\n   * Moderate CDI not responding to standard therapy (vancomycin) for at least a week. OR\n   * Severe C. difficile infection with toxic megacolon, not responding to standard therapy or the use of IVIg.\n3. Subject is willing and able to provide informed consent.\n4. If a female of childbearing potential, subject has agreed to use an acceptable form of birth control for up to 4 weeks after FMT treatment.\n\nExclusion Criteria:\n\n1. Subject is pregnant.\n2. Subject is unable to comply with study requirements.",{"count":121,"type":21},100,[24],"The objective of this study is to provide treatment with Fecal Microbiota Transplantation (FMT) to patients with recurrent or refractory Clostridium difficile infection (CDI). It has been shown that good bacteria (like that found in the stool from a healthy donor) attack Clostridium difficile in multiple ways: they make substances that kill Clostridium difficile - and they attach to the surface of the colon lining, which prevents the Clostridium difficile toxin (poison) from attaching.\n\nFMT involves infusing a mixture of saline and stool from a healthy donor into the bowel of the patient with CDI during a colonoscopy.\n\nThe method used to deliver the FMT will depend on individual characteristics of the subject and is at the discretion of the treating physician. FMT may be administered by the following methods.\n\n* Colonoscopy: This method allows full endoscopic examination of the colon and exclusion of comorbid conditions (such as IBD, malignancy or microscopic colitis) which may have an impact on subject's treatment or response to therapy.\n* Sigmoidoscopy: This method still allows infusion of the stool into a more proximal segment of the colon than an enema, but may not require sedation. This method may be beneficial in subjects who are elderly or multiparous and who may have difficulty retaining the material when given as enema. Sigmoidoscopic administration eliminates the additional risks associated with colonoscopy in subjects who may not have a clear indication for colonoscopy.\n* Retention enema: This method may be preferable in younger subjects who have already had recent endoscopic evaluation, in subjects who prefer not to undergo endoscopy or in subjects with significant co morbidities and may not tolerate endoscopy.\n\nThe physician will administer 300-500 mL of the fecal suspension in aliquots of 60 mL, through the colonoscope or sigmoidoscope or 150 mL via retention enema. In cases of colonoscopic delivery, the material will be delivered to the most proximal point of insertion.\n\nThe subject is encouraged to retain stool for as long as possible.",[125],"Clostridium Difficile Infection",[127,128,129],"C diff","CDI","clostridium difficile associated diarrhea","2025-04-11",{"date":132,"type":34},"2025-04-13",{"date":134,"type":4},"2013-07",{"date":136,"type":21},"2026-12",{"name":40,"class":41},""]